Hexafluronium Bromide

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317992

CAS#: 317-52-2 (bromide)

Description: Hexafluronium bromide is a neuromuscular blocking agent used in anesthesiology to prolong and potentiate the skeletal muscle relaxing action of suxamethonium during surgery. It is known to bind and block the activity of plasma cholinesterases. Hexafluronium acts as a nicotinic acetylcholine receptor antagonist.

Chemical Structure

img
Hexafluronium Bromide
CAS# 317-52-2 (bromide)
Instruction

Theoretical Analysis

MedKoo Cat#: 317992
Name: Hexafluronium Bromide
CAS#: 317-52-2 (bromide)
Chemical Formula: C36H42Br2N
Exact Mass: 660.17
Molecular Weight: 662.540
Elemental Analysis: C, 65.26; H, 6.39; Br, 24.12; N, 4.23

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 4844-10-4 (cation)   317-52-2 (bromide)    

Synonym: Hexafluronium Bromide; Mylaxen; Hexafluorenium bromide; Milaxen; Hexafluorenium dibromide; Esafluronio bromuro; hexafluorenium dibromide salt;

IUPAC/Chemical Name: 9H-fluoren-9-yl-[6-[9H-fluoren-9-yl(dimethyl)azaniumyl]hexyl]-dimethylazanium;dibromide

InChi Key: WDEFPRUEZRUYNW-UHFFFAOYSA-L

InChi Code: InChI=1S/C36H42N2.2BrH/c1-37(2,35-31-21-11-7-17-27(31)28-18-8-12-22-32(28)35)25-15-5-6-16-26-38(3,4)36-33-23-13-9-19-29(33)30-20-10-14-24-34(30)36;;/h7-14,17-24,35-36H,5-6,15-16,25-26H2,1-4H3;2*1H/q+2;;/p-2

SMILES Code: C[N+](C)(CCCCCC[N+](C)(C)C1C2=CC=CC=C2C3=CC=CC=C13)C4C5=CC=CC=C5C6=CC=CC=C46.[Br-].[Br-]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
Soluble in DMSO, not in water 0.0 100.00

Preparing Stock Solutions

The following data is based on the product molecular weight 662.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Britton RM, Figueroa M. Hexafluorenium bromide: current status and a review.
Anesth Analg. 1973 Jan-Feb;52(1):100-5. Review. PubMed PMID: 4567515.


2: Radnay PA, Badola RP, Dalsania A, El-Gaweet EI, Duncalf D. Prevention of
suxamethonium-induced changes in serum potassium concentration by hexafluorenium.
Is their combined use justified? Br J Anaesth. 1979 May;51(5):447-51. PubMed
PMID: 444345.


3: Radnay PA, El-Gaweet ES, Novakovic M, Badola R, Cizmar S, Duncalf D.
Prevention of succinylcholine induced hyperkalemia by neurolept anesthesia and
hexafluorenium in anephric patients. Anaesthesist. 1981 Jul;30(7):334-7. PubMed
PMID: 6455928.


4: Scaf AH, Langendijk JW. The desensitizing interaction of hexafluorenium with
the cholinergic receptor in the diaphragm of the rat. Arch Int Pharmacodyn Ther.
1977 Feb;225(2):196-207. PubMed PMID: 849069.


5: Baraka A. Hexafluorenium-suxamethonium interaction in patients with normal
versus atypical cholinesterase. Br J Anaesth. 1975 Aug;47(8):885-8. PubMed PMID:
1201167.


6: KATZ RL, GISSEN AJ, KARIS JH. THE EFFECTS OF HEXAFLUORENIUM AND EDROPHONIUM ON
THE NEUROMUSCULAR BLOCKING ACTIONS OF SUCCINYLCHOLINE, DECAMETHONIUM, IMBRETIL
AND D-TUBOCURARINE. Anesthesiology. 1965 Mar-Apr;26:154-61. PubMed PMID:
14261050.


7: RIZZI R, GIUSSANI A. [THE COMBINATION OF HEXAFLUORENIUM, SUCCINYLCHOLINE AND
FLUOTHANE IN ANESTHESIA. PRELIMINARY NOTE]. Acta Anaesthesiol. 1964
Jan-Feb;15:53-62. Italian. PubMed PMID: 14131757.


8: VAN HEMERTV. [CHOLINESTERASE INHIBITORS IN ANESTHESIA, WITH SPECIAL REFERENCE
TO HEXAFLUORENIUM (MYLAXEN)]. Ned Tijdschr Geneeskd. 1964 Oct 3;108:1931-2.
Dutch. PubMed PMID: 14242486.


9: NASTUK WL, KARIS JH. THE BLOCKING ACTION OF HEXAFLUORENIUM ON NEUROMUSCULAR
TRANSMISSION AND ITS INTERACTION WITH SUCCINYLCHOLINE. J Pharmacol Exp Ther. 1964
May;144:236-52. PubMed PMID: 14183436.


10: MOSTERT JW, KUENDIG H. EXPERIMENTAL STUDY OF ARRHYTHMIAS AND BRONCHOSPASM
ASSOCIATED WITH THE USE OF HEXAFLUORENIUM. Br J Anaesth. 1964 Feb;36:83-93.
PubMed PMID: 14117757.


11: JOBIDON A, PARADIS B, LABRECQUE A, DOUVILLE G. [HEXAFLUORENIUM, POTENTIATOR
OF SUCCINYLCHOLINE]. Can Anaesth Soc J. 1964 Jan;11:88-100. French. PubMed PMID:
14099695.


12: MOSTERT JW. [Hexafluorenium, antagonist of hexabiscarbacholine during
anesthesia in humans]. Can Anaesth Soc J. 1963 May;10:241-3. French. PubMed PMID:
13936235.


13: SOBEL AM. Hexafluorenium, succinylcholine, and intraocular tension. Anesth
Analg. 1962 Jul-Aug;41:399-404. PubMed PMID: 13914678.


14: FOLDES FF, MOLLOY RE, ZSIGMOND EK, ZWARTZ JA. Hexafluorenium: its
anticholinesterase and neuromuscular activity. J Pharmacol Exp Ther. 1960
Aug;129:400-4. PubMed PMID: 13823697.


15: FOLDES FF, HILLMER NR, MOLLOY RE, MONTE AP. Potentiation of the neuromuscular
effect of succinylcholine by hexafluorenium. Anesthesiology. 1960
Jan-Feb;21:50-8. PubMed PMID: 13823695.


16: Schuh FR. Interaction of hexafluorenium with human plasma cholinesterase in
comparison with hexamethonium. Naunyn Schmiedebergs Arch Pharmacol.
1976;293(1):11-3. PubMed PMID: 948350.


17: Scaf AH, van den Akker J, Berends F. The interactions of hexafluorenium with
depolarizing and competitive neuromuscular blocking agents. Arch Int Pharmacodyn
Ther. 1974 Mar;208(1):166-76. PubMed PMID: 4276930.


18: Vermeer GA, Hess SW. The potentiation of the neuromuscular blocking activity
of hexafluorenium and d-tubocurarine by volatile anaesthetics. Anaesthesist. 1974
Feb;23(2):72-8. PubMed PMID: 4458482.


19: Scaf AH. The interaction of the bisquaternary ammonium compound
hexafluorenium with the histaminic receptor in the guinea-pig ileum. Eur J
Pharmacol. 1971;15(3):363-5. PubMed PMID: 4258489.


20: Walts LF, DeAngelis J, Dillon JB. Clinical studies of the interaction of
hexafluorenium and succinylcholine in man. Anesthesiology. 1970 Nov;33(5):503-7.
PubMed PMID: 4249163.